Increased mortality in HIV-positive South African men versus women is unrelated to HIV/AIDS

September 4, 2012

In South Africa, HIV-infected men who are receiving treatment with anti-HIV drugs (antiretroviral therapy) are almost a third more likely to die than HIV-positive women who are receiving similar treatment: however, these differences are likely to be due to gender differences in death rates in the general population rather than related to HIV, according to a study by a team of international researchers published in this week's PLOS Medicine.

An international , led by Morna Cornell from the University of Cape Town, analyzed data collected from 46,201 adults who started taking antiretroviral therapy between 2002 and 2009 in eight programs in South Africa.

They found that at the start of treatment, men generally had a lower CD4 count (a of HIV activity—a lower count indicates increased infection) and were more likely to have advanced HIV disease than women. But even after allowing for these factors, the researchers found that HIV-positive men on antiretroviral therapy were almost a third (31%) more likely to die than HIV-positive women on similar treatment.

The researchers also found that men were more likely to be lost to follow up than women, but men and women who were lost to follow-up were equally likely to die. Furthermore, women had a slightly better immunological response to antiretroviral therapy than men but suppression of the was similar in both genders.

However, importantly, the researchers found that, the gender differences in the deaths rates they observed in this study were smaller than the gender differences in death rates (standardized by age) in the general (HIV-negative) South African population—a situation that may explain their results

The researchers say: "HIV-infected men have higher mortality on antiretroviral therapy than women in South African programmes, but these differences are only partly explained by more advanced HIV disease at the time of antiretroviral therapy initiation, differential loss-to-follow-up and subsequent mortality, and differences in responses to treatment."

They conclude: "The observed differences in mortality on antiretroviral therapy may be best explained by background differences in mortality between men and women in the South African population unrelated to the HIV/AIDS epidemic."

Explore further: Are there gender differences in anti-HIV drug efficacy?

More information: Cornell M, Schomaker M, Garone DB, Giddy J, Hoffmann CJ, et al. (2012) Gender Differences in Survival among Adult Patients Starting Antiretroviral Therapy in South Africa: A Multicentre Cohort Study. PLoS Med 9(9): e1001304. doi:10.1371/journal.pmed.1001304

Related Stories

Are there gender differences in anti-HIV drug efficacy?

August 9, 2012
Women comprise nearly half of the HIV-infected population worldwide, but these 15.5 million women tend to be under-represented in clinical trials of anti-HIV drug therapies. The U.S. Food and Drug Administration (FDA) has ...

Hope for more options in couples where one partner is HIV positive

November 15, 2011
In sub-Saharan Africa, couples in long-term relationships where one partner is HIV-positive and the other is HIV-negative (HIV serodiscordant couples) could benefit from anti-AIDS drugs (antiretroviral therapy) given either ...

Only one-third of HIV-positive patients remain in care before starting treatment

July 19, 2011
In sub-Saharan Africa, only about one third of patients who test positive for HIV but are not yet eligible for antiretroviral treatment remain in care until they become eligible and start treatment. Some patients never return ...

Study reveals 15-year increase in life expectancy for people with HIV in UK

October 12, 2011
People with HIV have a 15 years longer life expectancy thanks to improved treatments over the past 13 years, according to a new study published in the British Medical Journal today.

Recommended for you

Study suggests a way to stop HIV in its tracks

December 1, 2017
When HIV-1 infects an immune cell, the virus travels to the nucleus so quickly there's not enough time to set off the cell's alarm system.

Discovery puts the brakes on HIV's ability to infect

November 30, 2017
Viewed with a microscope, the virus faintly resembles a pineapple—the universal symbol of welcome. But HIV, the virus that causes AIDS, is anything but that. It has claimed the lives of more than 35 million people so far.

Rising levels of HIV drug resistance

November 30, 2017
HIV drug resistance is approaching and exceeding 10% in people living with HIV who are about to initiate or reinitiate first-line antiretroviral therapy, according to the largest meta-analysis to date on HIV drug resistance, ...

Male circumcision and antiviral drugs appear to sharply reduce HIV infection rate

November 29, 2017
A steep drop in the local incidence of new HIV infections accompanied the rollout of a U.S.-funded anti-HIV program in a large East-African population, according to a study led by researchers at Johns Hopkins Bloomberg School ...

Combination HIV prevention reduces new infections by 42 percent in Ugandan district

November 29, 2017
A study published today in the New England Journal of Medicine provides real-world evidence that implementing a combination of proven HIV prevention measures across communities can substantially reduce new HIV infections ...

Research on HIV viral load urges updates to WHO therapy guidelines

November 24, 2017
A large cohort study in South Africa has revealed that that low-level viraemia (LLV) in HIV-positive patients who are receiving antiretroviral treatment (ART) is an important risk factor for treatment failure.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.